Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.61 |
| ▸ | MET | P08581 | 2/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.54 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3275395 | 1.00 | SPHK2 (0.61) | SPHK2METHRH3SPHK1KDM4E | |
| SCHEMBL3275021 | 0.94 | MET (0.66) | SPHK2METHRH3SPHK1KDM4E | |
| SCHEMBL3275019 | 0.94 | MET (0.66) | SPHK2METHRH3SPHK1KDM4E | |
| SCHEMBL3276672 | 0.91 | SPHK2 (0.59) | SPHK2METHRH3SPHK1ALDH1A1 | |
| SCHEMBL3276667 | 0.91 | SPHK2 (0.59) | SPHK2METHRH3SPHK1ALDH1A1 | |
| SCHEMBL3274919 | 0.90 | SPHK2 (0.58) | SPHK2METHRH3SPHK1ALDH1A1 | |
| SCHEMBL3274911 | 0.90 | SPHK2 (0.58) | SPHK2METHRH3SPHK1ALDH1A1 | |
| SCHEMBL27927130 | 0.89 | SPHK2 (0.58) | SPHK2METHRH3SPHK1KDM4E | |
| SCHEMBL3275211 | 0.89 | ALDH1A1 (0.60) | SPHK2METHRH3KDM4EALDH1A1 | |
| SCHEMBL3275208 | 0.89 | ALDH1A1 (0.60) | SPHK2METHRH3KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756051-B1 | Histamine H3 receptor agents, preparation and therapeutic uses | LILLY CO ELI (US) | 2012-09-12 | — | — | EP | claimed |
| US-20090118254-A1 | (4-Benzyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)- methanone; obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY | 2009-05-07 | — | — | US | claimed |
| EP-1756051-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-02-28 | — | — | EP | claimed |
| WO-2005121080-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-22 | — | — | WO | claimed |
| EP-1756051-B1 | Histamine H3 receptor agents, preparation and therapeutic uses | LILLY CO ELI (US) | 2012-09-12 | — | — | EP | disclosed |
| EP-1756051-B1 | Histamine H3 receptor agents, preparation and therapeutic uses | LILLY CO ELI (US) | 2012-09-12 | — | — | EP | disclosed |
| US-7696234-B2 | (4-Benzyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)- methanone; obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696234-B2 | (4-Benzyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)- methanone; obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696234-B2 | (4-Benzyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)- methanone; obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY (US) | 2010-04-13 | — | — | US | disclosed |
| US-20090118254-A1 | (4-Benzyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)- methanone; obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY | 2009-05-07 | — | — | US | disclosed |
| US-20090118254-A1 | (4-Benzyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)- methanone; obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY | 2009-05-07 | — | — | US | disclosed |
| US-20090118254-A1 | (4-Benzyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)- methanone; obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118254-A1 | (4-Benzyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)- methanone; obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | HRH3, HRH4, HCRTR1 | SPHK2 720/4885MET 903/4885HRH3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.